Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Domestic Tenofovir (Qingzhong) vs Viread in Chinese Chronic Hepatitis B
NCT02287857Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Decline of serum HBV-DNA from baseline at 48 weeks. Status: unknown.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02287857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287857.